Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Non-Current Assets (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Non-Current Assets for 16 consecutive years, with $39.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 1.62% to $39.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $150.5 million through Dec 2025, down 10.9% year-over-year, with the annual reading at $39.8 million for FY2025, 1.62% up from the prior year.
  • Non-Current Assets hit $39.8 million in Q4 2025 for Cumberland Pharmaceuticals, up from $36.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $51.4 million in Q1 2022 to a low of $36.0 million in Q3 2025.
  • Historically, Non-Current Assets has averaged $42.8 million across 5 years, with a median of $42.6 million in 2021.
  • Biggest five-year swings in Non-Current Assets: decreased 18.54% in 2021 and later rose 21.36% in 2022.
  • Year by year, Non-Current Assets stood at $38.8 million in 2021, then grew by 21.36% to $47.1 million in 2022, then decreased by 2.11% to $46.1 million in 2023, then dropped by 15.05% to $39.1 million in 2024, then rose by 1.62% to $39.8 million in 2025.
  • Business Quant data shows Non-Current Assets for CPIX at $39.8 million in Q4 2025, $36.0 million in Q3 2025, and $36.7 million in Q2 2025.